ClinicalTrials.gg
RecruitingNCT06181656Updated May 20, 2026

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

An observational study in Pneumococcal Vaccine, Esophageal Cancer and Lymphopenia, sponsored by M.D. Anderson Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center — 5 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · M.D. Anderson Cancer Center.

Started
2024
with 1 other
Observational
9 of 29
2 open now
Registered
27th of 29
by date

Among the 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center, this one is one of 2 that started in 2024, is one of 9 observational ones, and was the 27th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

5 of the 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Esophageal Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

To learn how radiation treatment may affect your responses to vaccines against pneumonia.

Read the detailed description

Primary Objectives

- Determine the impact of Grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination.

Secondary Objectives

  • Determine the impact of chemoradiation on serologic responses to pneumococcal vaccination.
  • Determine the impact of radiation modality on serologic responses to pneumococcal vaccination.
  • Determine the impact of radiation modality on systemic immunity.
  • Determine the incidence of pneumonia among patients treated with a pneumococcal vaccine.
  • Determine the impact of radiation modality on pathologic response.
  • Determine the impact of radiation modality on intratumoral immunity.
  • Determine the relationship between changes in systemic and intratumoral immunity and clinical outcomes (i.e., incidence of pneumonia and pathologic response)
  • Determine the impact of tumor histology on serologic responses to pneumococcal vaccination.
03

Conditions studied

  • Pneumococcal Vaccine
  • Esophageal Cancer
  • Lymphopenia
  • Chemoradiation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

MD Anderson Cancer Center will enroll 30 esophageal cancer patients. Massachusetts General Hospital in Boston, MA will enroll 30 HCC patients. MD Anderson Cancer Center \& Massachusetts General Hospital in Boston will jointly enroll up to 20 health volunteers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Group 1A

    a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons.

  2. Group 1B

    a. Patients currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (IMRT)

  3. Group 2A

    a. Patients currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable liver cancer.

  4. Group 2B

    a. Patients currently receiving, planning to receive, or recently completed definitive IMRT for unresectable liver cancer.

  5. Group 3

    a. Healthy age- and gender- matched individuals

  6. All Groups

    1. Patients of all genders, races and nationalities will be solicited.
    2. Age >18 years
    3. Ability to understand and the willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  • Patients with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., (HIV), X-linked agammaglobulinemia) or previous or current immune suppressive therapy

    a. Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.

  • Patients receiving intravenous immunoglobulin (IVIG) during the study or in the three months prior to study enrollment.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Individuals with previous pneumococcal vaccination in the last 5 years.
  • Individuals with severe allergy to any of the vaccine components
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    30 participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer. This group will be subdivided into Group 1A, which will comprise 15 participants treated with proton therapy, and Group 1B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).

    Biological: Pneumonia vaccine

  • Group 2

    30 participants currently receiving, planning to receive, or recently completed chemoradiation for hepatocellular carcinoma. This group will be subdivided into Group 2A, which will comprise 15 participants treated with proton therapy, and Group 2B, which will comprise 15 patients treated with intensity modulated radiation therapy (IMRT).

    Biological: Pneumonia vaccine

  • Group 3

    20 Healthy Volunteers.

    Biological: Pneumonia vaccine

Interventions

  • BiologicalPneumonia vaccine

    Given by SC

06

What researchers measure

Primary outcomes

  1. Impact of grade IV radiation-induced lymphopenia on serologic responses to pneumococcal vaccination

    Serologic responses will be calculated as the average fold change in antibody titer for each of 20 pneumococcal serotypes between baseline (time 0) and the first post-vaccination blood draw.

    Time frame: through study completion; an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jul 2027, 40 months after the start.

Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 40 months is below that.

Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Feb 5, 2024
Primary completionEst.
Jul 4, 2027
CompletionEst.
Jul 4, 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06181656
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Feb 5, 2024
Primary completion
Jul 4, 2027 (estimated)
Completion
Jul 4, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Steven H Lin, MD
Contact
shlin@mdanderson.org
(713) 563-8490
Steven H Lin, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion